Identification of fluocinolone acetonide to stop paclitaxel-induced peripheral neuropathy.
J Peripher Nerv Syst. 2016 Sep;21(three):128-33
Authors: Cetinkaya-Fisgin A, Joo MG, Ping X, Thakor NV, Ozturk C, Hoke A, Yang IH
Paclitaxel (PTX) is among the many mostly used most cancers medication that trigger chemotherapy-induced peripheral neuropathy (CIPN), a debilitating and severe dose-limiting facet impact. Presently, no medication exist to stop CIPN, and symptomatic remedy is commonly ineffective. As a way to establish therapeutic candidates to stop axonal degeneration induced by PTX, we carried out a phenotypic drug screening utilizing major rodent dorsal root ganglion sensory neurons. We recognized fluocinolone acetonide as a neuroprotective compound and verified it by way of secondary screens. Moreover, we confirmed its efficacy in a mouse mannequin of PTX-induced peripheral neuropathy and confirmed with 4 completely different most cancers cell traces that fluocinolone acetonide doesn’t intrude with PTX’s antitumor exercise. Our research identifies fluocinolone acetonide as a possible remedy to stop CIPN attributable to PTX.
PMID: 27117347 [PubMed – indexed for MEDLINE]